KOSDAQBiotech & Pharma0007J0

Inventera

₩8,550▲ 21.79%2026-11-18 close
Market Cap
₩67.7B
Turnover
₩1.3B
Volume
160K
Shares out.
7.9M
PER
—
PBR
1.7×
EPS
—
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q1–2025Q4) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

After Phase 3 Success, Approval and Revenue Conversion Are the Focus

Inventera has completed the domestic Phase 3 trial of its nano MRI contrast agent INV-002 and plans to file for approval in Q4 2026, while disclosed results show operating losses widening through Q3 2026.

  1. 1

    INV-002 met all primary and secondary endpoints in its domestic Phase 3 trial, as disclosed on September 21, 2026.

  2. 2

    On disclosed figures, the operating loss for 2025 was KRW 8.6 billion and the net loss attributable to controlling shareholders was KRW 8.05 billion, both wider than in 2024.

  3. 3

    Operating losses were KRW 1.91 billion, KRW 2.49 billion and KRW 2.66 billion in Q1 to Q3 2026, three consecutive quarters of losses with each quarter larger than the last.

  4. 4

    At the end of 2025, total equity was KRW 14.3 billion and total liabilities were KRW 1.15 billion, with the debt ratio rising from 5.6% in 2024 to 8.1% in 2025.

  5. 5

    The company said it expects INV-002 sales to start in earnest from 2027 after approval.

02

Business structure

Inventera is a nano-medicine developer founded in November 2018 that develops high-resolution MRI contrast agents and supplies them to hospitals and pharmaceutical companies under a B2B model.

Its core platform is the in-house nanostructure platform Invinity, which the company positions as a differentiator because it uses iron-based materials instead of gadolinium to achieve MRI contrast.

The pipeline spans musculoskeletal, lymphatic and pancreatobiliary areas, and in musculoskeletal imaging the lead candidate is INV-002 (generic name NEMO-103 juu).

INV-002 is a drug dedicated to MR arthrography, and it met both primary and secondary endpoints in its domestic Phase 3 trial, as disclosed in September 2026. The lymphatic contrast agent INV-001 is also in the pipeline.

A pancreatobiliary diagnostic agent received news of US Phase 1 trial plan approval in late October 2026. The CEO has described a model in which Inventera handles everything from original technology to product approval in-house, then partners with capable commercial partners to generate stable revenue.

As of June 2026, a corporate profile service listed the company as clinical-stage and pre-commercial, with no sales recorded.

Segment revenue mix does not apply at this stage, and the main competitive comparison is the iron-based material against gadolinium-based contrast agents, which the company says reduces rare-earth supply-chain risk.

As of June 26, 2026, the largest shareholders were Shin Tae-hyun and one other person with 18.88% and Gong Eun-ah with 11.08%.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3———
2025Q4———
2026Q1₩0-₩1.9B—
2026Q2₩0-₩2.5B—
2026Q3₩0-₩2.7B—
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2024₩0-₩6.4B-₩6B—−28.7%5.6%
2025₩0-₩8.6B-₩8B—−56.4%8.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

On disclosed annual figures, the operating loss widened from KRW 6.37 billion in 2024 to KRW 8.6 billion in 2025, a continued loss that deepened year on year, and the company has posted losses in two consecutive years from 2024 to 2025.

The net loss attributable to controlling shareholders grew from KRW 6.04 billion in 2024 to KRW 8.05 billion in 2025, and the consolidated net loss including non-controlling interests was also KRW 6.04 billion in 2024 and KRW 8.05 billion in 2025.

Operating cash flow went from -KRW 4.49 billion in 2024 to -KRW 6.34 billion in 2025, so the cash outflow grew.

The debt ratio rose from 5.6% in 2024 to 8.1% in 2025, and at the end of 2025 total equity was KRW 14.3 billion, of which controlling shareholders' equity was also KRW 14.3 billion, with total liabilities of KRW 1.15 billion. The quarterly series has no figures for Q3 and Q4 2025, so it starts in Q1 2026.

The operating loss was KRW 1.91 billion in Q1 2026, KRW 2.49 billion in Q2 and KRW 2.66 billion in Q3, a loss that widened each quarter.

Net losses attributable to controlling shareholders over the same period were KRW 1.82 billion, KRW 2.26 billion and KRW 2.52 billion, moving in the same direction as operating losses.

The four quarterly net losses attributable to controlling shareholders from Q1 to Q4 2025 total KRW 8.05 billion, the same as the annual figure for 2025. With no revenue, costs are the main driver of the loss, so the size of the loss is likely to be sensitive to the intensity of clinical and approval activity.

Cost line items, however, need to be checked in the notes to the regular report. Because the disclosed series starts in 2024, the long-term trend can only be read across two years, and Q4 2026 results are expected to be disclosed in the 2026 annual report.

05

Industry analysis

Inventera was classified as a pharmaceutical company in the wave of new listings in the first half of 2026, and it listed on KOSDAQ on April 2, 2026. The MRI contrast agent market has relied on gadolinium-based materials, and rare-earth gadolinium supply risk is seen as a structural burden.

Inventera presents its iron-based technology as an alternative that addresses this material supply risk. Its customers are hospitals and pharmaceutical companies, and the company says it earns revenue through both product sales and technology transfer.

In terms of cycle position, the company has completed Phase 3 and is just ahead of commercialization, so whether approval is obtained is the dividing line for entering the revenue stage.

Compared with larger listed peers in the same biopharma sector such as Celltrion and Samsung Biologics, which generate earnings from sales, Inventera is at a different business stage, so comparisons should focus on pipeline progress and approval timing.

INV-002, a musculoskeletal-focused contrast agent, is the first commercial candidate, so differences in indications from existing agents could be a variable in how fast prescriptions spread.

Platform differentiation lies in expanding from diagnostics into therapeutics and antibody-drug conjugates, and how this strategy is positioned within the sector needs further checking.

06

Outlook

The company said it plans to submit the approval application for INV-002 to the Ministry of Food and Drug Safety within Q4 2026. The CEO said he expects INV-002 sales to begin in earnest from 2027, after approval.

Under the business model, sales after product launch are described as being generated through cooperation with commercial partners.

The independent research firm Aris said in a report dated October 20, 2026 that the company had entered a commercialization phase on completion of INV-002 Phase 3, and it projected a turnaround driven by a global technology transfer in 2028.

Expansion into therapeutics and ADCs is presented as a medium- to long-term direction, with Drug Conjugate and Invinity-ADC research ongoing. The pancreatobiliary contrast agent has received news of US Phase 1 trial plan approval, which is cited as support for pipeline expansion.

The points to check are whether the approval application is completed, the review progress, and the terms of agreements with commercial partners. Given no revenue at present, whether operating losses continue will determine if post-approval sales growth translates into narrower losses.

In the 2026 annual report, the first checkpoint is how the annual operating loss and net loss attributable to controlling shareholders moved compared with KRW 8.6 billion and KRW 8.05 billion in 2025.

07

Valuation

PER
—
PBR
1.7×
ROE
-56.4%
EPS
—
BPS
₩4,162
Dividend per share
₩0

Because the company has been loss-making over the last four quarters, a price-to-earnings ratio cannot be calculated, and valuation comparison based on earnings is difficult at this stage. The price-to-book ratio is above 1 times, which means the shares trade at a premium to book value.

Setting total equity of KRW 14.3 billion against the 2025 net loss attributable to controlling shareholders of KRW 8.05 billion, the annual loss is above half of equity. The company does not pay dividends, so a comparison on dividend yield does not apply.

Trading history since the 2026 listing is short, which limits the use of a past trading band as a reference for current positioning. The valuation discussion rests on the outcome of the INV-002 approval and pipeline progress, and the basis for a premium to book value depends on whether approval is granted.

The 2028 turnaround projection by one research firm relies on a distant assumption, so reading the current share price also requires checking whether that assumption is realized.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Domestic Phase 3 success and approval filing plan

INV-002 met all primary and secondary endpoints in its domestic Phase 3 trial, as disclosed in September 2026. The company plans to file for approval with the Ministry of Food and Drug Safety in Q4 2026 and expects sales to ramp from 2027 after approval. If approval is granted, the company would enter product revenue for the first time.

Iron-based technology without gadolinium

The Invinity platform achieves contrast with iron-based materials, which the company presents as a way to move away from reliance on rare-earth gadolinium. This has been cited as reducing global supply-chain risk. Its focus on musculoskeletal indications also creates a position distinct from existing contrast agents.

Pipeline expansion and external outlook

In a report dated October 20, 2026, the independent research firm Aris projected a turnaround driven by a global technology transfer in 2028. The projection depends on a specific deal timing, so whether it materializes needs to be checked.

09

Bear factors

Widening losses with no revenue

As of June 2026, a corporate profile service recorded the company as clinical-stage with no sales. On disclosed figures, operating losses were KRW 1.91 billion, KRW 2.49 billion and KRW 2.66 billion in Q1 to Q3 2026, each larger than the previous quarter. Continued losses until approval are a bearish factor.

Signs of shrinking financial capacity

Total equity was KRW 14.3 billion at the end of 2025 and total liabilities were KRW 1.15 billion, but the debt ratio rose from 5.6% in 2024 to 8.1% in 2025. Operating cash flow was -KRW 6.34 billion, a larger outflow than -KRW 4.49 billion in 2024. The 2025 net loss attributable to controlling shareholders of KRW 8.05 billion is above half of total equity.

Concentrated ownership and a low free float

As of June 26, 2026, Shin Tae-hyun and one other person held 18.88%, and Gong Eun-ah held 11.08%. The free float ratio was recorded at 53.71%. A concentrated shareholder structure can amplify volatility in share supply and demand.

10

Risk factors

Approval and clinical risk

The approval application is still at the planning stage, and the timing and outcome of review are outside the company's control. A delay in approval would also push back the expected start of sales in 2027.

The pancreatobiliary agent is at the US Phase 1 entry stage, so follow-on clinical results are still some way off.

Dependence on commercial partners

The company handles everything from original technology to approval in-house and plans to generate sales through partnerships. Terms of partnerships and the timing of technology transfers could change the revenue and profit structure. Details of any partnership contracts will need to be checked through disclosures.

Financing and funding

Operating cash outflows increased while the company has no sales, and total equity was KRW 14.3 billion at the end of 2025. If losses continue, the need for additional funding could grow, and whether existing shareholders are diluted would become an issue. Funding plans should be checked against the cash flow items in the regular reports.

11

What to watch next

  1. By end of December 2026 (within Q4 2026)

    Whether the INV-002 approval application is submitted. If filed as planned, the product moves to review; a delay would push back the 2027 sales start.

  2. By March 31, 2027

    Filing of the 2026 annual report. The first checkpoint is how the 2026 annual operating loss and net loss attributable to controlling shareholders compare with KRW 8.6 billion and KRW 8.05 billion in 2025.

  3. During 2027 (approval timing not fixed)

    Whether the Ministry of Food and Drug Safety grants approval and whether INV-002 sales begin. The company has said it expects sales to ramp from 2027 after approval.

  4. After December 2026 (schedule not disclosed)

    Progress of the US Phase 1 trial for the pancreatobiliary diagnostic agent. Patient enrollment and whether results are disclosed will indicate how far pipeline expansion can go.

12

Overall view

Inventera is a nano MRI contrast agent company moving into the approval filing stage, centered on INV-002, which has completed domestic Phase 3.

On disclosed figures, the 2025 operating loss was KRW 8.6 billion and the net loss attributable to controlling shareholders was KRW 8.05 billion, both wider than in 2024, and losses have continued for three consecutive quarters from Q1 to Q3 2026.

Operating cash outflows have grown while the company has no sales, and the debt ratio rose from 5.6% to 8.1%. On the bullish side are the Phase 3 success, the gadolinium-free iron-based technology, and pipeline progress such as US Phase 1 approval for the pancreatobiliary agent.

On the bearish side are the absence of sales before approval, concentrated largest-shareholder ownership, and a low free float. Because earnings-based valuation cannot be calculated, the approval outcome and pipeline progress are the premise for assessment.

The next checkpoints are whether the approval application is filed in Q4 2026 and the annual loss size in the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. thevc.kr
  2. comp.wisereport.co.kr
  3. news.nate.com
  4. ket.kr
  5. ket.kr
  6. ustockplus.com
  7. marketwzd.com
  8. marketin.edaily.co.kr
  9. biotimes.co.kr
  10. kr.investing.com
  11. stocktitan.net
  12. prnewswire.com
  13. fool.com
  14. gurufocus.com
  15. globenewswire.com
  16. kr.investing.com
  17. gurufocus.com
  18. kr.investing.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis